secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001641172-25-001176
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air subsidiary NeuroNOS secures $2M initial funding for autism therapy development
--------------------------------------------------------------------------------

- NeuroNOS raised $2M initial equity from private investors as part of a larger round up to $5M total.
- Proceeds will accelerate preclinical development of a small-molecule drug targeting nitric oxide dysregulation in autism.
- First-in-human clinical trial anticipated to begin in 2026; formulation optimization for subcutaneous injection underway.
- After initial close, Beyond Air Ireland holds ~88% of NeuroNOS; would fall to ~75% if all $5M shares sold.
- Drug stems from Hebrew University research showing NO inhibition improves autism phenotypes in animal models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000164117225001176/0001641172-25-001176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000164117225001176/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer